Humanized anti-tau antibodies
Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.
1. An isolated monoclonal anti-tau antibody comprising
a light chain comprising the amino acid sequence of SEQ ID NO: 2, and
a heavy chain comprising the amino acid sequence of SEQ ID NO: 5.
2. The antibody of claim 1 , wherein the antibody is a humanized IgG1, IgG2, IgG3, or IgG4 antibody.
3. The antibody of claim 1 , wherein the antibody is a humanized IgG4 antibody containing a S241P hinge stabilizing mutation.
4. The antibody of claim 1 , wherein the antibody binds an epitope comprising an amino acid sequence of SEQ ID NO: 9.
5. A pharmaceutical composition comprising the anti-tau antibody of claim 1 and a pharmaceutically acceptable carrier.
6. An isolated monoclonal anti-tau antibody comprising
a light chain comprising the amino acid sequence of SEQ ID NO: 18; and
a heavy chain comprising the amino acid sequence of SEQ ID NO: 13.
7. A pharmaceutical composition comprising the anti-tau antibody of claim 6 and a pharmaceutically acceptable carrier.
8. The antibody of claim 6 , wherein the antibody binds an epitope comprising an amino acid sequence of SEQ ID NO: 9.
9. A nucleic acid molecule encoding an antibody light chain comprising the amino acid sequence of SEQ ID NO: 2, and an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 5.
10. The nucleic acid molecule of claim 9 that encodes a light chain comprising the amino acid sequence of SEQ ID NO: 18, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 13.
11. The antibody of claim 1 , wherein the antibody comprises a light chain constant region of human isotype kappa.
12. A pharmaceutical composition comprising the anti-tau antibody of claim 3 and a pharmaceutically acceptable carrier.